Experience

Adivo Associates LLC

• United States
• Business Consulting and Services
• 1 - 100 Employee

• Consultant

  • Feb 2022 - Present

  As a consultant, my role involves monitoring and modelling complex market environments for specialty pharmaceuticals, market opportunity assessments, as well as competitive tracking in the range of therapeutic areas like rare diseases, hematology, bone health and biosurgery: - Competition mapping - Patient segmentation - Market archetype (Payers, pricing, patients, channels, accounts…) - Forecasting / uptake analysis … As a consultant, my role involves monitoring and modelling complex market environments for specialty pharmaceuticals, market opportunity assessments, as well as competitive tracking in the range of therapeutic areas like rare diseases, hematology, bone health and biosurgery: - Competition mapping - Patient segmentation - Market archetype (Payers, pricing, patients, channels, accounts…) - Forecasting / uptake analysis …



Augur Associates

• France
• Business Consulting and Services
• 1 - 100 Employee

• Medical Cannabis - Consultant

  • Jan 2021 - Dec 2021



CarthaGenetics®

• Switzerland
• Business Consulting and Services
• 1 - 100 Employee

• Country Manager & Regulatory Head - Orphan Diseases

  • Jan 2019 - Nov 2020

  Regulatory watch on new early access tools and evolution of the legislation in Europe

• Country Manager - Rare Diseases - France & Italy

  • Oct 2015 - Nov 2020

  Carthagenetics is an international consulting company specializing in orphan drugs. We work every day to help international biotechnology companies involved in the development of orphan drugs to succeed in their arrival on the European market. Position: Country Manager France / Italy Therapeutic area: - Lysosomal diseases: Ultragenyx Pharmaceuticals & MPS VII (MEPSEVII); Enzyvant & Farber's disease (RVT-801); Vtesse & Niemann-Pick type C (VTS-270); Amicus & Fabry disease… Show more Carthagenetics is an international consulting company specializing in orphan drugs. We work every day to help international biotechnology companies involved in the development of orphan drugs to succeed in their arrival on the European market. Position: Country Manager France / Italy Therapeutic area: - Lysosomal diseases: Ultragenyx Pharmaceuticals & MPS VII (MEPSEVII); Enzyvant & Farber's disease (RVT-801); Vtesse & Niemann-Pick type C (VTS-270); Amicus & Fabry disease (Migalastat) - Rare Neurological Diseases: Ultragenyx & GLUT1D (UX007); Ultragenyx & GNE Myopathy (Ace-ER); PTC Therapeutics & Duchenne Muscular Dystrophy (EMFLAZA); Alnylam & ATTR Amyloidosis (Patisiran) - Other metabolic diseases: RegenXBio & Homozygous familial hypercholesterolemia / HoFH (RGX-501); PromeThera & Urea Cycle Deficit / UCD (HEPASTEM) - Hemato-oncology: Race Oncology & Refractory acute myeloid leukemia / RR AML - Infectiology: INSMED & NTMPD Missions: - Identification and creation of a relationship of trust with all actors specializing in rare disease: KOLs / expert centers / patient associations ... - Support for recruiting patients for clinical trials, selection sites, investigator support and interface with CROs - Help in defining the national strategy for the pre-launch of the orphan drug candidate and support on regulatory tools for early access programs (EAP). France: Nominative ATU ++ (AAC); Italy: Legge 326 / Legge 648 - Support for the creation of medical information campaigns on the pathology and questionnaires for medical practice - Organization of awareness activities on rare pathology (round tables) - Customer representation during contacts with ANSM - Representation at national and European medical congresses



Roche

• Switzerland
• Biotechnology Research
• 700 & Above Employee

• New Product & Business Development Intern

  • Apr 2014 - Oct 2014

  Inside the "Pipeline Product Strategy Team", responsible for projects of new molecules in development from Phase II to maximize the success of their future commercialization, my missions were: - Elaborate in-depth analysis on current and future markets in Oncology, Hematology, Neurology and Infectiology : Market trends, Epidemiology, Guidelines analysis, KOL/Advocacy groups/Digital environment mapping, in order to contribute to the elaboration of strategic recommendations. - Early… Show more Inside the "Pipeline Product Strategy Team", responsible for projects of new molecules in development from Phase II to maximize the success of their future commercialization, my missions were: - Elaborate in-depth analysis on current and future markets in Oncology, Hematology, Neurology and Infectiology : Market trends, Epidemiology, Guidelines analysis, KOL/Advocacy groups/Digital environment mapping, in order to contribute to the elaboration of strategic recommendations. - Early Market Access analysis for payer-aligned late phase clinical development. - Collaborate with Market Research, Health Economics, Medical, Clinical Operations, and Marketing teams to provide targeted business and market intelligence reviews and support local market forecast development. - Prepare communication supports for experts consultations, strategic committees and internal disease area awareness. Show less Inside the "Pipeline Product Strategy Team", responsible for projects of new molecules in development from Phase II to maximize the success of their future commercialization, my missions were: - Elaborate in-depth analysis on current and future markets in Oncology, Hematology, Neurology and Infectiology : Market trends, Epidemiology, Guidelines analysis, KOL/Advocacy groups/Digital environment mapping, in order to contribute to the elaboration of strategic recommendations. - Early… Show more Inside the "Pipeline Product Strategy Team", responsible for projects of new molecules in development from Phase II to maximize the success of their future commercialization, my missions were: - Elaborate in-depth analysis on current and future markets in Oncology, Hematology, Neurology and Infectiology : Market trends, Epidemiology, Guidelines analysis, KOL/Advocacy groups/Digital environment mapping, in order to contribute to the elaboration of strategic recommendations. - Early Market Access analysis for payer-aligned late phase clinical development. - Collaborate with Market Research, Health Economics, Medical, Clinical Operations, and Marketing teams to provide targeted business and market intelligence reviews and support local market forecast development. - Prepare communication supports for experts consultations, strategic committees and internal disease area awareness. Show less



Beckman Coulter Diagnostics

• United States
• Medical Equipment Manufacturing
• 700 & Above Employee

• Strategic Marketing Intern

  • May 2013 - Aug 2013

  Internship in Strategic Marketing (BU Monoclonal Antibodies in Flow Cytometry), my missions were: - Business intelligence and benchmarking to implement a new multitask database (FileMaker) gathering all the competitor's product informations, pricing and publications. - Market study for a new cell fixator in flow cytometry: Contact scientists in pharmaceutical companies to catch their need and insights. Internship in Strategic Marketing (BU Monoclonal Antibodies in Flow Cytometry), my missions were: - Business intelligence and benchmarking to implement a new multitask database (FileMaker) gathering all the competitor's product informations, pricing and publications. - Market study for a new cell fixator in flow cytometry: Contact scientists in pharmaceutical companies to catch their need and insights.



Hôpital d'Enfants de la Timone

• Medical Practices
• 100 - 200 Employee

• Externe

  • Jan 2013 - Apr 2013

  Pharmacy extern in Regulatory Affairs for an ANSM Expert in Clinical studies and Toxicology. Study and validation of the bioequivalence label of generic drugs (MA) for the French Drug Administration (ANSM) right after the apparition of a new regulatory. Pharmacy extern in Regulatory Affairs for an ANSM Expert in Clinical studies and Toxicology. Study and validation of the bioequivalence label of generic drugs (MA) for the French Drug Administration (ANSM) right after the apparition of a new regulatory.



Fundación de Hemoterapia y Hemodonación de Castilla y León

• Wellness and Fitness Services
• 1 - 100 Employee

• Extern (ERASMUS)

  • Oct 2012 - Jan 2013